<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CAPTOPRIL </span><br/>(kap'toe-pril)<br/><span class="topboxtradename">Capoten<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin-converting enzyme (ace) inhibitor</span>; <span class="classification">antihypertensive agent</span><br/><b>Prototype: </b>Enalapril<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>12.5 mg, 25 mg, 50 mg, 100 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Lowers blood pressure by specific inhibition of the angiotensin-converting enzyme (ACE). This interrupts conversion sequences
         initiated by renin that lead to formation of angiotensin II, a potent endogenous vasoconstrictor. ACE inhibition alters hemodynamics
         without compensatory reflex tachycardia or changes in cardiac output (except in patients with CHF). Peripheral vascular resistance
         is lowered by vasodilation. Inhibition of ACE also leads to decreased circulating aldosterone. Reduced circulating aldosterone
         is associated with a potassium-sparing effect. In heart failure, captopril administration is followed by a fall in CVP and
         pulmonary wedge pressure; hypotensive action appears to be unrelated to plasma renin levels.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective in stepped protocol management of hypertension to convert to normotensive range, and in congestive heart failure
         with resulting decreases in dyspnea and improved exercise tolerance.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension; in conjunction with digitalis and diuretics in CHF, diabetic nephropathy, left ventricular dysfunction post
         MI.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Idiopathic edema.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Angioedema, hypersensitivity to captopril or ACE inhibitors; hypotension; pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired renal function, patient with solitary kidney; collagen-vascular diseases (scleroderma, SLE); patients receiving <small>IMMUNOSUPPRESSANTS</small> or other drugs that cause leukopenia or agranulocytosis; autoimmune disease, bone marrow suppression, coronary or cerebrovascular
         disease; cardiomyopathy, aortic stenosis; severe salt/volume depletion; heart failure, renal artery stenosis, renal disease,
         renal failure, renal impairment; hyperkalemia, children, elderly.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 6.2525 mg t.i.d., may increase to 50 mg t.i.d. (max: 450 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.312.5 mg/kg q1224h, may titrate up to max of 6 mg/kg/d in 24 divided doses<br/><span class="rdage">Infant:</span> <span class="rdroute">PO</span> 0.150.3 mg/kg, may titrate up to 6 mg/kg/d in 14 divided doses<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO</span> 0.050.1 mg/kg q824 h, may titrate up to 0.5 mg/kg q624 h<br/><span class="rdage">Premature infant:</span> <span class="rdroute">PO</span> 0.01 mg/kg q812h<br/><br/><span class="indicationtitle">Congestive Heart Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 6.2512.5 mg t.i.d., may increase to 100 mg t.i.d. (max: 450 mg/d) <br/><br/><span class="indicationtitle">Renal Insufficiency</span><br/><span class="rdroute"></span> Cl<sub>cr</sub> 1050 mL/min = 75% of dose, Cl<sub>cr</sub> </td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give captopril 1 h before meals. Food reduces absorption by 3040%.</li>
<li>Store in light-resistant containers at no more than 30° C (86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Hypersensitivity reactions, serum sickness-like reaction, arthralgia, skin eruptions. <span class="typehead">CV:</span> Slight increase in heart rate, first dose hypotension, dizziness, fainting. <span class="typehead">GI:</span> Altered taste sensation (loss of taste perception, persistent salt or metallic taste); weight loss, intestinal angioedema. <span class="typehead">Hematologic:</span> Hyperkalemia, neutropenia, <span class="speceff-life">agranulocytosis</span> (rare). <span class="typehead">Respiratory:</span>
<span class="speceff-common">cough</span>. <span class="typehead">Skin:</span>
<span class="speceff-common">Maculopapular rash,</span> urticaria, pruritus, <span class="speceff-life">angioedema</span>, photosensitivity. <span class="typehead">Urogenital:</span> Azotemia, impaired renal function, nephrotic syndrome, membranous glomerulonephritis. <span class="typehead">Other:</span> Positive antinuclear antibody (ANA) titers. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>In some patients, elevated <span class="alt">urine protein levels</span> may persist even after captopril has been discontinued. Possibility of transient elevations of <span class="alt">BUN</span> and <span class="alt">serum creatinine,</span> slight increase in <span class="alt">serum potassium,</span> and <span class="alt">serum prolactin,</span> increases in <span class="alt">liver enzymes,</span> and false-positive <span class="alt">urine acetone</span> (using <span class="alt">sodium nitroprusside reagent</span>). Captopril may decrease <span class="alt">fasting blood sugar</span> in the nondiabetic and cause hypoglycemia in the diabetic patient controlled with antidiabetic drug therapy.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">nitrates</span>, <span class="classification">diuretics</span>, and <span class="classification">antihypertensives</span> enhance hypotensive effects. <b>Aspirin</b> and other <span class="classification">nsaids</span> may antagonize hypotensive effects. <span class="classification">potassium-sparing diuretics</span> (<b>spironolactone,</b>
<b>amiloride</b>) increase <b>potassium</b> levels. <b>Probenecid</b> decreases elimination and increases effects. <span class="typehead">Food:</span> Food decreases absorption; take 3060 min before meals. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 6075% absorbed; food may decrease absorption 2540%. <span class="typehead">Onset:</span> 15 min. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 612 h. <span class="typehead">Distribution:</span> Distributed to all tissues except CNS; crosses placenta. <span class="typehead">Metabolism:</span> Some liver metabolism. <span class="typehead">Elimination:</span> Excreted primarily in urine; excreted in breast milk. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP closely following the first dose. A sudden exaggerated hypotensive response may occur within 13 h of first
            dose, especially in those with high BP or on a diuretic and restricted salt intake.
         </li>
<li>Advise bed rest and BP monitoring for the first 3 h after the initial dose.</li>
<li>Monitor therapeutic effectiveness. At least 2 wk of therapy may be required before full therapeutic effects are achieved.</li>
<li>Lab tests: Establish baseline urinary protein levels before initiation of therapy and check at monthly intervals for the first
            8 mo of treatment and then periodically thereafter. Perform WBC and differential counts before therapy is begun and at approximately
            2-wk intervals for the first 3 mo of therapy and then periodically thereafter.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician without delay the onset of unexplained fever, unusual fatigue, sore mouth or throat, easy bruising or
            bleeding (pathognomonic of agranulocytosis).
         </li>
<li>Mild skin eruptions are most likely to appear during the first 4 wk of therapy and may be accompanied by fever and eosinophilia.</li>
<li>Consult physician promptly if vomiting or diarrhea occur.</li>
<li>Report darkening or crumbling of nailbeds (reversible with dosage reduction).</li>
<li>Taste impairment occurs in 510% of patients and generally reverses in 23 mo even with continued therapy.</li>
<li>Use OTC medications only with approval of the physician. Inform surgeon or dentist that captopril is being taken. Alert diabetic
            patient that captopril may produce hypoglycemia. Monitor blood glucose and HbA<sub>1c</sub> closely during first few weeks of therapy.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>